Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 31.43 Million SEK | 214.21% |
| 2022 | 10 Million SEK | 74.88% |
| 2021 | 5.72 Million SEK | -20.67% |
| 2020 | 7.21 Million SEK | 29.95% |
| 2019 | 5.55 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | -100.0% |
| 2013 | 6.65 Million SEK | -26.74% |
| 2012 | 9.08 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 17.12 Million SEK | -44.6% |
| 2024 Q3 | 9.83 Million SEK | -42.57% |
| 2024 Q1 | 30.91 Million SEK | -1.68% |
| 2023 FY | 31.43 Million SEK | 214.21% |
| 2023 Q3 | 25.52 Million SEK | -91.05% |
| 2023 Q2 | 285.09 Million SEK | -2.69% |
| 2023 Q4 | 31.43 Million SEK | 23.16% |
| 2023 Q1 | 292.98 Million SEK | 2828.39% |
| 2022 Q4 | 10 Million SEK | 80.43% |
| 2022 Q1 | 5.14 Million SEK | -10.09% |
| 2022 FY | 10 Million SEK | 74.88% |
| 2022 Q3 | 5.54 Million SEK | -13.68% |
| 2022 Q2 | 6.42 Million SEK | 24.88% |
| 2021 FY | 5.72 Million SEK | -20.67% |
| 2021 Q1 | 6.9 Million SEK | -4.33% |
| 2021 Q2 | 5.79 Million SEK | -16.03% |
| 2021 Q3 | 4.67 Million SEK | -19.38% |
| 2021 Q4 | 5.72 Million SEK | 22.48% |
| 2020 Q2 | 47.86 Million SEK | 373.78% |
| 2020 Q3 | 74.48 Million SEK | 55.61% |
| 2020 Q4 | 7.21 Million SEK | -90.32% |
| 2020 Q1 | 10.1 Million SEK | 82.04% |
| 2020 FY | 7.21 Million SEK | 29.95% |
| 2019 Q4 | 5.55 Million SEK | -92.19% |
| 2019 FY | 5.55 Million SEK | 0.0% |
| 2019 Q1 | 55.05 Million SEK | 0.0% |
| 2019 Q2 | 67.35 Million SEK | 22.33% |
| 2019 Q3 | 71.04 Million SEK | 5.48% |
| 2018 Q3 | 40.82 Million SEK | 7.38% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | 30.35 Million SEK | 0.0% |
| 2018 Q2 | 38.01 Million SEK | 25.22% |
| 2018 Q4 | - SEK | -100.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | 25.24 Million SEK | 0.0% |
| 2017 Q2 | 28.76 Million SEK | 13.96% |
| 2017 Q3 | 30.18 Million SEK | 4.92% |
| 2017 Q4 | - SEK | -100.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q1 | 11.81 Million SEK | 77.37% |
| 2014 Q2 | 15.89 Million SEK | 34.6% |
| 2014 Q3 | - SEK | -100.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | -100.0% |
| 2013 Q4 | 6.65 Million SEK | 11.47% |
| 2013 Q2 | 79 Thousand SEK | -25.47% |
| 2013 FY | 6.65 Million SEK | -26.74% |
| 2013 Q1 | 106 Thousand SEK | -98.83% |
| 2013 Q3 | 5.97 Million SEK | 7462.03% |
| 2012 Q4 | 9.08 Million SEK | 0.0% |
| 2012 FY | 9.08 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 98.052% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 98.052% |
| Arcoma AB | 3.87 Million SEK | -711.696% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 86.513% |
| BICO Group AB (publ) | 1.85 Billion SEK | 98.304% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 81.073% |
| CellaVision AB (publ) | 64.7 Million SEK | 51.413% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -6824.449% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -1646.5% |
| Duearity AB (publ) | 10.58 Million SEK | -197.08% |
| Dignitana AB (publ) | 19.1 Million SEK | -64.557% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -504.558% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.611% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | -281.072% |
| Iconovo AB (publ) | 7.72 Million SEK | -306.956% |
| Integrum AB (publ) | 6.42 Million SEK | -389.354% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -15158.902% |
| Mentice AB (publ) | 9.55 Million SEK | -228.942% |
| OssDsign AB (publ) | 3.15 Million SEK | -898.0% |
| Paxman AB (publ) | 13.57 Million SEK | -131.665% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | -51.642% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -362.513% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 1.104% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -630.074% |
| Senzime AB (publ) | 11.46 Million SEK | -174.128% |
| SpectraCure AB (publ) | 6.71 Million SEK | -368.021% |
| Stille AB | 62.94 Million SEK | 50.054% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 98.495% |